Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study / Hamid, O; Hassel, Jc; Shoushtari, An; Meier, F; Bauer, Tm; Salama, Aks; Kirkwood, Jm; Ascierto, Pa; Lorigan, Pc; Mauch, C; Orloff, M; Evans, Trj; Holland, C; Edukulla, R; Abedin, Se; Middleton, Mr. - In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. - ISSN 2051-1426. - (2023). [10.1136/jitc-2023-006747]
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
Ascierto PA;Mauch C;
2023
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
